BICO Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

BICO Group hat ein Gesamteigenkapital von SEK3.1B und eine Gesamtverschuldung von SEK1.4B, was einen Verschuldungsgrad von 47.1% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK5.9B bzw. SEK2.9B.

Wichtige Informationen

47.1%

Verhältnis von Schulden zu Eigenkapital

SEK 1.44b

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 795.70m
Eigenkapital	SEK 3.06b
Gesamtverbindlichkeiten	SEK 2.87b
Gesamtvermögen	SEK 5.92b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 49ZDie kurzfristigen Aktiva des Unternehmens (SEK1.8B) übersteigen seine kurzfristigen Passiva (SEK723.6M).

Langfristige Verbindlichkeiten: 49ZDie kurzfristigen Vermögenswerte des Unternehmens (SEK1.8B) decken seine langfristigen Verbindlichkeiten (SEK2.1B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 49ZDie Nettoverschuldung im Verhältnis zum Eigenkapital (21.1%) wird als zufriedenstellend angesehen.

Schulden abbauen: 49ZDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 1% auf 47.1% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: 49Z auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: 49Z verfügt über eine ausreichende Liquiditätsreserve für 1.9 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 33.1% pro Jahr abnimmt.

BICO Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

New minor risk - Profitability

No longer forecast to breakeven

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)

New major risk - Revenue and earnings growth

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

Group Chief Financial Officer recently bought €75k worth of stock

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Full year 2022 earnings released: kr13.00 loss per share (vs kr3.97 loss in FY 2021)

Independent Chairman of the Board recently sold €747k worth of stock

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

Now 28% undervalued

Third quarter 2022 earnings released

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

Forecast breakeven date moved forward to 2022

Second quarter 2022 earnings released

Forecast breakeven date moved forward to 2022

Now 22% undervalued after recent price drop

First quarter 2022 earnings released: kr0.68 loss per share (vs kr0.90 loss in 1Q 2021)

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

Now 23% undervalued after recent price drop

High number of new and inexperienced directors

BICO Group AB (Publ) Announces Board Appointments

Co-Founder recently bought €94k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

Co-Founder recently bought €1.9m worth of stock

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

Third quarter 2021 earnings released

Insider recently sold €1.1m worth of stock

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CEO & Director recently sold €17m worth of stock

Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

First quarter 2021 earnings released

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

New 90-day high: €30.00

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

New 90-day high: €25.25

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

New 90-day high: €21.65

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Full year earnings released - €1.47 loss per share

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

New 90-day high: €18.06

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.